Press Room

DDL 2020

Start
Wednesday, December 09, 2020 - 00:00
End
Friday, December 11, 2020 - 00:00
Location: online
Drug Delivery To The Lungs 2020 logo | Hovione

Register for free and access the DDL2020 live virtual event here and visit Hovione’s booth.

Do not miss Hovione's Scientists presentations:

Flash Presentation 

December 11, 2020, 13:45 - 13:55

​​​​​Benchmarking of particle engineering technologies for nasal powder manufacture

Flash Speaker: Patricia Henriques





On-Demand Presentation nr.7

Exploring the potential and practicalities of semi-automation in inhaler testing

Presenters: Raquel Borda D’Agua (Hovione) & Anna Sipitanou (Copley)





On-Demand Presentation nr.15

Spray-dried composite formulation for lung sustained release

Presenter: Beatriz Noriega Fernandes 

 

 

Schedule a meeting today

and connect with one of our Inhalation Experts

 

Take advantage of cutting-edge particle engineering technologies highly skilled responsive staff and state of the art analytical facilities.

 

 

Inhalation high performance APIs particle engineering formulation DPIs pdf | Hovione

 

Everything for Inhalation

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026